This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
The trial missed its primary endpoint, but makes unique contributions; many see it as further evidence that the treatment helps iron-deficient patients with heart failure.
The American Heart Association (AHA) Scientific Sessions 2022 in Chicago, and virtually, is set for November 5-7 at McCormick Place. Highly-anticipated clinical trial breakthroughs and discoveries of the year will be offered in both late-breaking scientific sessions and featured science sessions.
Patients with heart failure and mitral regurgitation should get at least 6 months of optimized guideline-directed medical therapy before invasive mitral repair is considered, researchers say.